Baxter International Inc.

NYSE:BAX

Medical - Instruments & Supplies

Healthcare
$26.16 -5.23%

-$1.07 today

Market cap
$13.53B
Beta
0.64
P/E (TTM)
-9.1
EPS (TTM)
-$2.13
Dividend yield
1.03%
52W Low $15.73High $31.76

Volume 4.01M

Average 7.62M

BAX EBITDA Margin

EBITDA as a percentage of revenue.

Baxter International Inc.NYSE: BAX

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin holds steady near 16.0%

EBITDA Margin was 16.0% in Q2 FY2026, down 0.4 pp from a year earlier. On a trailing-twelve-month basis it was 6.5%, down 3.0 pp year over year. Over 3 fiscal years it widened by 24.3 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 11 analysts of 20.9% for the fiscal year ending Dec 2026, up from 6.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
16.0%+5.0 pp QoQ
Last fiscal yearDec 2025
6.8%-3.7 pp YoY
LTMJun 2026
6.5%-3.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-0.4 pp+4.9 pp+5.3 pp
1 year-3.7 pp+14.1 pp+17.8 pp
3 years+24.3 pp+12.7 pp-11.6 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
6.8%
Year-over-year change
-3.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How BAX compares with its peers on the latest reported figures

  • BAX's LTM Jun 2026 EBITDA Margin of 6.5% is the lowest of the 5 companies compared; the peer median is 17.9%.
  • Its year-over-year change of -3.0 pp is the lowest of 5, against a peer median of +0.3 pp.
  • Over three fiscal years its change of +24.3 pp compares with a peer median of +2.8 pp.
BAX Competitors Peer median
EBITDA Margin for BAX and competitors
Company Period LTM level YoY 3-year change
DVADaVita Inc.LTM Jun 202619.7% -0.9 pp+1.7 pp
INFUInfuSystem Holdings, Inc.LTM Mar 202618.2% +2.6 pp+4.0 pp
FMSFresenius Medical Care AG & Co. KGaALTM Jun 202617.6% +1.4 pp-0.3 pp
ICUIICU Medical, Inc.LTM Jun 202611.5% -2.1 pp+5.5 pp
BAXBaxter International Inc.LTM Jun 20266.5% -3.0 pp+24.3 pp
Peer median (excluding BAX) 17.9%+0.3 pp+2.8 pp

Competitors are the stored peer set for BAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.15B10.06B10.36B10.64B11.24B
Cost of Revenue7.43B6.51B6.21B6.65B7.87B
Gross Profit4.72B3.55B4.15B3.98B3.38B
Gross Margin38.9%35.3%40.1%37.5%30.1%
Research & Development531M450M518M590M518M
Selling, General & Admin2.85B3.1B2.95B2.97B2.89B
Operating Expenses3.37B6.39B3.44B3.97B3.69B
Depreciation & Amortization867M1.07B984M997M981M
EBITDA2.19B(1.76B)1.73B1.12B766M
EBITDA Margin18.0%-17.5%16.7%10.5%6.8%
Operating Income1.35B(2.85B)707M14M(308M)
Operating Margin11.1%-28.3%6.8%0.1%-2.7%
Interest Income14M19M69M67M52M
Interest Expense207M413M508M408M290M
Other Income / Expenses(234M)(403M)(465M)(303M)(197M)
Income Before Tax1.12B(3.25B)242M(289M)(505M)
Pre-Tax Margin9.2%-32.3%2.3%-2.7%-4.5%
Income Tax Expense83M(135M)61M37M395M
Net Income1.28B(2.43B)2.66B(649M)(957M)
Net Margin10.6%-24.2%25.6%-6.1%-8.5%
EPS (Basic)2.56(4.83)5.25(1.27)(1.75)
EPS (Diluted)2.53(4.83)5.23(1.27)(1.75)
Weighted Avg Shares502M504M506M510M513M
Weighted Avg Shares (Diluted)508M504M506M510M513M

Baxter International Inc.

NYSE:BAX

Intrinsic Alpha fair value

Locked

Current Price

$26.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.